On October 2, 2015, the U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab). This approval, designated as BLA 125514 S-5, specifically addresses an efficacy claim, expanding the therapeutic applications of this important drug. The application was sponsored by Merck Sharp Dohme.
Background
Pembrolizumab, known commercially as Keytruda, is a well-established pharmaceutical. Supplemental approvals from the FDA are granted when a manufacturer seeks to add new indications, update dosing regimens, or expand the patient population for an already approved drug. In this instance, the approval pertains directly to the drug's efficacy, meaning new clinical data supported its benefit in a specific context. This process allows for the continuous evolution of a drug's label as more research becomes available, providing clinicians with updated guidance on its use.
What this means
This supplemental efficacy approval for Keytruda (pembrolizumab) signifies that new clinical evidence has demonstrated the drug's effectiveness for an additional or expanded indication. For healthcare providers, this means an updated label for pembrolizumab, potentially offering a new treatment option for patients within the scope of the approved efficacy claim. Patient advocates and researchers will note this as an expansion of available therapies, potentially leading to improved outcomes for specific patient groups. The FDA's decision is based on a thorough review of data submitted by Merck Sharp Dohme, confirming the drug's benefit-risk profile for the newly approved use.
Source
The details of this supplemental approval are publicly available from the U.S. Food and Drug Administration (FDA). The specific approval, identified by BLA 125514 S-5, was issued on October 2, 2015, and can be verified on the FDA's website at accessdata.fda.gov.